Prenetics Global has appointed veteran consumer analyst Caroline Levy as an independent director, adding more than three decades of experience in consumer research, capital markets and corporate governance. Levy’s background includes senior leadership roles at UBS and CLSA, as well as board experience at Celsius Holdings. The appointment comes as Prenetics prepares to report its second-quarter 2026 results, putting greater attention on whether IM8’s rapid growth can translate into a scalable global consumer health business.

Veteran Consumer Analyst Joins Prenetics Board

Prenetics Global has appointed Caroline Levy to its board as an independent director, strengthening the company’s consumer-sector and capital-markets experience at a potentially important stage of its development. Levy has spent more than 30 years analyzing consumer companies and was ranked among Wall Street’s leading consumer analysts by Institutional Investor and The Wall Street Journal.

Her career includes a decade at UBS, where she led U.S. consumer research, served as Chief Operating Officer of Research and chaired the Investment Review Committee. She subsequently spent eight years as a managing director and senior analyst at CLSA before most recently covering the beverage sector at Macquarie.

For Prenetics, the appointment adds a director with experience evaluating consumer brands from an investment perspective while also bringing direct corporate governance experience. Levy currently serves on the board of Celsius Holdings, where she has been a director since 2020.

IM8 Growth Raises the Strategic Stakes

Levy joins the board as Prenetics continues positioning IM8 as the central growth engine of its consumer health strategy. The company describes IM8 as an AI-native direct-to-consumer wellness brand co-founded by David Beckham and says the business surpassed $200 million in annualized run-rate revenue within 18 months of launch.

IM8 currently ships to 43 countries and delivers approximately 200,000 servings daily, according to Prenetics. Its expansion has also been supported by a growing roster of ambassadors and equity partners, including David Beckham, Giannis Antetokounmpo, Aryna Sabalenka, Ollie Bearman and Jay Shetty.

The scale of those figures creates both an opportunity and a higher standard for execution. Rapid consumer-brand growth must ultimately be supported by customer retention, efficient marketing, product development and disciplined deployment of capital. Levy’s experience across consumer companies could therefore become particularly relevant as Prenetics attempts to move IM8 from a fast-growing brand into a more established global platform.

Board Experience Arrives Ahead of Q2 Results

The timing of the appointment is also notable because Prenetics is scheduled to report its second-quarter 2026 financial results on August 18. Chief Executive Officer Danny Yeung and Chief Financial Officer Brian Rosin are expected to present the company’s results and outlook during the earnings webcast, followed by a question-and-answer session with research analysts.

Investors will likely focus on whether the company’s rapid growth remains intact and how management plans to support the next stage of expansion. The company’s own disclosure also highlights several risks, including the potential need for additional capital, maintaining customer engagement, managing the IM8 brand and efficiently deploying financial and management resources.

Levy’s appointment does not by itself change those fundamentals, but it could strengthen the board’s ability to evaluate strategic decisions as the company scales.

Market Outlook

Prenetics enters its next phase with significant growth ambitions for IM8 and a newly expanded board that brings deeper consumer and governance experience. The immediate catalyst will be the second-quarter earnings report, which should provide investors with additional information about revenue momentum, operating performance and management’s expectations for the remainder of 2026. Over the longer term, the key question will be whether IM8 can sustain its rapid international expansion while improving the efficiency and durability of its consumer model. If Prenetics can demonstrate that its growth is supported by repeat demand, disciplined investment and expanding operating scale, Levy’s appointment could prove strategically valuable as the company moves toward a larger global consumer-health platform.